Monopar Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Monopar Therapeutics Inc. (MNPR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 3.08 thousand shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2026-08-12
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2026-06-30 was 3.08K shares, a 67.71% decline year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2026-03-31 was 62.23K shares, a 71.23% decline year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-12-31 was 54.69K shares.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-09-30 was 22.50K shares, a 19.06% decline year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2025 was 303.07K shares, a 596.35% increase from fiscal 2024.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2024 was 43.52K shares, a 57.24% decline from fiscal 2023.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2023 was 101.79K shares, a 83.15% decline from fiscal 2022.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2022 was 604.06K shares, a 49.71% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 3.08K shares 10-Q · filed 2026-08-12 | 65.31K shares 10-Q · filed 2026-08-12 | 120.00K shares derived: sum of 3 quarters · filed 2026-08-12 | 142.50K shares derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | 62.23K shares 10-Q · filed 2026-05-14 | 116.92K shares derived: sum of 2 quarters · filed 2026-05-14 | 139.42K shares derived: sum of 3 quarters · filed 2026-05-14 | 148.97K shares derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | 54.69K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | 77.19K shares derived: sum of 2 quarters · filed 2026-03-27 | 86.74K shares derived: sum of 3 quarters · filed 2026-08-12 | 303.07K shares 10-K · filed 2026-03-27 | ||||
| 2025-09-30 | 22.50K shares 10-Q · filed 2025-11-13 | 32.05K shares derived: sum of 2 quarters · filed 2026-08-12 | 248.38K shares 10-Q · filed 2025-11-13 | 248.38K shares derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | 9.55K shares 10-Q · filed 2026-08-12 | 225.88K shares 10-Q · filed 2026-08-12 | 225.88K shares derived: sum of 3 quarters · filed 2026-08-12 | 253.68K shares derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | 216.33K shares 10-Q · filed 2026-05-14 | 216.33K shares derived: sum of 2 quarters · filed 2026-05-14 | 244.13K shares derived: sum of 3 quarters · filed 2026-05-14 | 257.85K shares derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | 27.80K shares derived: sum of 2 quarters · filed 2026-03-27 | 41.52K shares derived: sum of 3 quarters · filed 2026-03-27 | 43.52K shares 10-K · filed 2026-03-27 | ||||
| 2024-09-30 | 27.80K shares 10-Q · filed 2025-11-13 | 41.52K shares derived: sum of 2 quarters · filed 2025-11-13 | 43.52K shares 10-Q · filed 2025-11-13 | 43.52K shares derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | 13.72K shares 10-Q · filed 2025-08-12 | 68.59K shares 10-Q · filed 2024-08-09 | 15.72K shares 10-Q · filed 2025-08-12 | 78.59K shares 10-Q · filed 2024-08-09 | 15.72K shares derived: sum of 3 quarters · filed 2025-08-12 | 15.72K shares derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | 2.00K shares 10-Q · filed 2025-05-13 | 10.00K shares 10-Q · filed 2024-05-09 | 2.00K shares derived: sum of 2 quarters · filed 2025-05-13 | 2.00K shares derived: sum of 3 quarters · filed 2025-05-13 | 2.00K shares derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 0.00 shares derived: sum of 2 quarters · filed 2025-03-31 | 0.00 shares derived: sum of 3 quarters · filed 2025-03-31 | 101.79K shares 10-K · filed 2025-03-31 | 508.90K shares 10-K · filed 2024-03-28 | |||
| 2023-09-30 | 0.00 shares 10-Q · filed 2024-11-08 | 0.00 shares derived: sum of 2 quarters · filed 2024-11-08 | 101.79K shares 10-Q · filed 2024-11-08 | 508.90K shares 10-Q · filed 2023-11-09 | 530.90K shares derived: sum of 4 quarters · filed 2024-11-08 | |||
| 2023-06-30 | 0.00 shares 10-Q · filed 2024-08-09 | 508.90K shares 10-Q · filed 2024-08-09 | 530.90K shares derived: sum of 3 quarters · filed 2024-08-09 | 534.90K shares derived: sum of 4 quarters · filed 2024-08-09 | ||||
| 2023-03-31 | 508.90K shares 10-Q · filed 2024-05-09 | 530.90K shares derived: sum of 2 quarters · filed 2024-05-09 | 534.90K shares derived: sum of 3 quarters · filed 2024-05-09 | 559.90K shares derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | 22.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 26.00K shares derived: sum of 2 quarters · filed 2024-03-28 | 51.00K shares derived: sum of 3 quarters · filed 2024-03-28 | 604.06K shares 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | 4.00K shares 10-Q · filed 2023-11-09 | 29.00K shares derived: sum of 2 quarters · filed 2023-11-09 | 582.06K shares 10-Q · filed 2023-11-09 | 585.06K shares derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | 25.00K shares 10-Q · filed 2023-08-10 | 578.06K shares 10-Q · filed 2023-08-10 | 581.06K shares derived: sum of 3 quarters · filed 2023-08-10 | 680.06K shares derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | 553.06K shares 10-Q · filed 2023-05-11 | 556.06K shares derived: sum of 2 quarters · filed 2023-05-11 | 655.06K shares derived: sum of 3 quarters · filed 2023-05-11 | 760.06K shares derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | 3.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | 102.00K shares derived: sum of 2 quarters · filed 2023-03-23 | 207.00K shares derived: sum of 3 quarters · filed 2023-03-23 | 403.48K shares 10-K · filed 2023-03-23 | ||||
| 2021-09-30 | 99.00K shares 10-Q · filed 2022-11-10 | 204.00K shares derived: sum of 2 quarters · filed 2022-11-10 | 400.48K shares 10-Q · filed 2022-11-10 | 400.48K shares derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | 105.00K shares 10-Q · filed 2022-08-11 | 301.48K shares 10-Q · filed 2022-08-11 | 301.48K shares derived: sum of 3 quarters · filed 2022-08-11 | 308.48K shares derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | 196.48K shares 10-Q · filed 2022-05-12 | 196.48K shares derived: sum of 2 quarters · filed 2022-05-12 | 203.48K shares derived: sum of 3 quarters · filed 2022-05-12 | |||||
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | 7.00K shares derived: sum of 2 quarters · filed 2022-03-24 | 174.36K shares 10-K · filed 2022-03-24 | |||||
| 2020-09-30 | 7.00K shares 10-Q · filed 2021-11-12 | 174.36K shares 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |